Metabolic Outcomes of Changing From Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine to Rilpivirine/Tenofovir Alafenamide/Emtricitabine: A Longitudinal Study

Overview

Journal Health Sci Rep

Specialty General Medicine

Date 2024 Dec 19

PMID 39698519

Authors

Ping-Feng Wu

Hsi-Hsun Lin

Hsin-Pai Chen

Po-Chieh Huang

Meng-Yu Ke

Affiliations

Soon will be listed here.

Abstract

Background And Aims: People living with human immunodeficiency virus (HIV, PLWH) are aging, and there are growing concerns regarding combined antiretroviral therapy (cART)-associated negative metabolic consequences. We aimed to investigate the metabolic outcomes of PLWH by replacing rilpivirine (RPV)/tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) with RPV/tenofovir alafenamide (TAF)/FTC.

Methods: This retrospective study enrolled PLWH who changed from RPV/TDF/FTC to RPV/TAF/FTC between January 2019 and September 2023. Metabolic profiles were compared 1 year before and 3 years after changing cART using Cochran's and one-way ANOVA. The independent risk factors for metabolic syndrome were analyzed using logistic regression.

Results: A total of 182 patients were enrolled. The prevalence of metabolic syndrome has increased from 28% to 40.7%. The prevalence of hypertension and abnormal lipid levels significantly increased in the first year after changing cART, but the prescription of medicine for dyslipidemia increased in the second year ( = 0.025) and that for hypertension increased in the third year ( < 0.001). In addition to the criteria, body mass index (BMI) before changing cART was the only predictor of metabolic syndrome in the third year (OR 1.36; 95% CI 1.19-1.55; < 0.001). The prevalence of metabolic syndrome and BMI did not increase significantly during the second and third years.

Conclusions: A gradually higher prevalence of metabolic syndrome among PLWH occurred with changes from RPV/TDF/FTC to RPV/TAF/FTC but plateaued beyond 2 years. However, fewer drugs for dyslipidemia, diabetes, and hypertension were prescribed within the first year after changing cART.

References

Gallant J, Daar E, Raffi F, Brinson C, Ruane P, DeJesus E . Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind,.... Lancet HIV. 2016; 3(4):e158-65. DOI: 10.1016/S2352-3018(16)00024-2. View

Palacios R, Santos J, Gonzalez M, Ruiz J, Marquez M . Incidence and prevalence of the metabolic syndrome in a cohort of naive HIV-infected patients: prospective analysis at 48 weeks of highly active antiretroviral therapy. Int J STD AIDS. 2007; 18(3):184-7. DOI: 10.1258/095646207780132415. View

Lagoutte-Renosi J, Flammang M, Chirouze C, Beck-Wirth G, Bozon F, Brunel A . Real-Life Impact on Lipid Profile of a Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected Patients. Curr HIV Res. 2020; 19(1):84-89. DOI: 10.2174/1570162X18666200824101838. View

Schafer J, Sassa K, OConnor J, Shimada A, Keith S, DeSimone J . Changes in Body Mass Index and Atherosclerotic Disease Risk Score After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide. Open Forum Infect Dis. 2019; 6(10):ofz414. PMC: 6786703. DOI: 10.1093/ofid/ofz414. View

Chang H . Weight Gain and Metabolic Syndrome in Human Immunodeficiency Virus Patients. Infect Chemother. 2022; 54(2):220-235. PMC: 9259920. DOI: 10.3947/ic.2022.0061. View

Han W, Law M, Choi J, Ditangco R, Kumarasamy N, Chaiwarith R . Weight changes, metabolic syndrome and all-cause mortality among Asian adults living with HIV. HIV Med. 2021; 23(3):274-286. PMC: 8847330. DOI: 10.1111/hiv.13211. View

Teeraananchai S, Kerr S, Amin J, Ruxrungtham K, Law M . Life expectancy of HIV-positive people after starting combination antiretroviral therapy: a meta-analysis. HIV Med. 2016; 18(4):256-266. DOI: 10.1111/hiv.12421. View

Martinez-Sanz J, Serrano-Villar S, Muriel A, Garcia Fraile L, Orviz E, de Cea A . Metabolic-Related Outcomes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Adults With Human Immunodeficiency Virus (HIV): A Multicenter Prospective Cohort Study. Clin Infect Dis. 2022; 76(3):e652-e660. DOI: 10.1093/cid/ciac621. View

Hansen B, Petersen J, Haugaard S, Madsbad S, Obel N, Suzuki Y . The prevalence of metabolic syndrome in Danish patients with HIV infection: the effect of antiretroviral therapy. HIV Med. 2009; 10(6):378-87. DOI: 10.1111/j.1468-1293.2009.00697.x. View

10.

Jumare J, Dakum P, Sam-Agudu N, Memiah P, Nowak R, Bada F . Prevalence and characteristics of metabolic syndrome and its components among adults living with and without HIV in Nigeria: a single-center study. BMC Endocr Disord. 2023; 23(1):160. PMC: 10375691. DOI: 10.1186/s12902-023-01419-x. View

11.

Cooper R, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M . Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis. 2010; 51(5):496-505. DOI: 10.1086/655681. View

12.

Jacobson D, Tang A, Spiegelman D, Thomas A, Skinner S, Gorbach S . Incidence of metabolic syndrome in a cohort of HIV-infected adults and prevalence relative to the US population (National Health and Nutrition Examination Survey). J Acquir Immune Defic Syndr. 2006; 43(4):458-66. DOI: 10.1097/01.qai.0000243093.34652.41. View

13.

Rethy L, Feinstein M, Achenbach C, Townsend R, Bress A, Shah S . Antihypertensive Class and Cardiovascular Outcomes in Patients With HIV and Hypertension. Hypertension. 2021; 77(6):2023-2033. PMC: 8119362. DOI: 10.1161/HYPERTENSIONAHA.120.16263. View

14.

. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV. 2017; 4(8):e349-e356. PMC: 5555438. DOI: 10.1016/S2352-3018(17)30066-8. View

15.

Huang Y, Cheng C, Sun H, Cheng S, Lu P, Lee C . Week 96 Results of Switching from Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide among HIV/Hepatitis B Virus-Coinfected Patients. Microbiol Spectr. 2023; 11(3):e0512522. PMC: 10269761. DOI: 10.1128/spectrum.05125-22. View

16.

Hagins D, Orkin C, Daar E, Mills A, Brinson C, DeJesus E . Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials. HIV Med. 2018; 19(10):724-733. PMC: 6221083. DOI: 10.1111/hiv.12664. View

17.

Todowede O, Mianda S, Sartorius B . Prevalence of metabolic syndrome among HIV-positive and HIV-negative populations in sub-Saharan Africa-a systematic review and meta-analysis. Syst Rev. 2019; 8(1):4. PMC: 6317235. DOI: 10.1186/s13643-018-0927-y. View

18.

Gupta S, Post F, Arribas J, Eron Jr J, Wohl D, Clarke A . Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials. AIDS. 2019; 33(9):1455-1465. PMC: 6635043. DOI: 10.1097/QAD.0000000000002223. View

19.

Surial B, Mugglin C, Calmy A, Cavassini M, Gunthard H, Stockle M . Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV : A Cohort Study. Ann Intern Med. 2021; 174(6):758-767. DOI: 10.7326/M20-4853. View

20.

Ayodele O, Akinboro A, Akinyemi S, Adepeju A, Akinremi O, Alao C . Prevalence and clinical correlates of metabolic syndrome in Nigerians living with human immunodeficiency virus/acquired immunodeficiency syndrome. Metab Syndr Relat Disord. 2012; 10(5):373-9. DOI: 10.1089/met.2012.0050. View